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Abstract
Pulmonary involvement in leptospirosis is emerging as a common complication of severe leptospirosis. A prospective randomized con-
trolled trial of desmopressin or high-dose (pulse) dexamethasone as adjunctive therapy in 68 patients with pulmonary involvement asso-
ciated with severe leptospirosis was conducted between July 2003 and October 2006 at ﬁve hospitals in Thailand. There were 23
patients in the desmopressin group, 22 in the pulse dexamethasone group, and 23 in a control group who received standard critical
care alone. The diagnosis of leptospirosis was conﬁrmed in 52 patients (77%). There were 15 deaths (22%), of which eight patients
received desmopressin, four patients received pulse dexamethasone, and three patients received critical care alone (p 0.19). Eight
patients with conﬁrmed leptospirosis died (ﬁve patients in the desmopressin group, one in the pulse dexamethasone group and two in
the control group). The mortality was not signiﬁcantly different in the desmopressin group or pulse dexamethasone group compared to
the control group in both intention-to-treat patients, and in patients with conﬁrmed leptospirosis. There were no serious events associ-
ated with desmopressin treatment, although pulse dexamethasone treatment was associated with a signiﬁcant increase in nosocomial
infection. The results of logistic regression analysis revealed that serum bilirubin level was the only signiﬁcant risk factor associated with
mortality (OR 0.759, 95% CI 0.598–0.965, p 0.024). The results obtained in the present study do not support the use of either pulse
dexamethasone or desmopressin as adjunct therapy for pulmonary involvement associated with severe leptospirosis.
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Introduction
Leptospirosis is a zoonosis, with a worldwide distribution,
caused by pathogenic members of genus Leptospira. Clinical
manifestations of human leptospirosis vary from subclinical
infection, self-limited anicteric febrile illness, to a severe and
potentially fatal illness known as Weil’s syndrome [1].
Pulmonary involvement in leptospirosis has been reported
to be increasing, and is emerging as the main cause of death in
this disease in many countries, including Thailand. The
reported mortality rate of severe pulmonary involvement is in
the range 40–75% [2–6]. The pathogenesis of lung abnormali-
ties in leptospirosis is not completely understood. Two main
mechanisms have been suggested: a toxin-mediated capillary
vasculitis [7] and/or exacerbated immune responses of the
host [8,9]. On the basis of this proposed pathogenic mecha-
nism of lung injuries, high-dose or pulse dexamethasone and
methylprednisolone have been used in patients with severe
pulmonary involvement of leptospirosis [10,11]. Desmopres-
sin, a selective vasopressin V2 receptor agonist, has been
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used successfully to improve haemostatic deﬁciencies in
mild hemophilia A, Type I von Willebrand disease, platelet
disorders, and in acquired bleeding as a result of renal failure,
or hepatic cirrhosis [12]. Desmopressin and high-dose
gluocorticosteroid were shown to be potential adjunctive
treatments for leptospirosis in uncontrolled case series
[10,11,13]. In the present study, we report a prospective
randomized trial aiming to evaluate the efﬁcacy of pulse
dexamethasone or desmopressin as adjunct treatment in
patients with pulmonary involvement associated with severe
leptospirosis.
Materials and Methods
Patients and study sites
The study was conducted at ﬁve hospitals in Thailand, four in
the northeast (Udon Thani Hospital, Udon Thani Province;
Maharat Nakhon Ratchasima Hospital, Nakhon Ratchasima
Province; Loei Hospital, Loei Province; and Chaiyapoom Hos-
pital, Chaiyapoom Province) and one in the south (Chumphon
Hospital, Chumphon Province). Inclusion criteria were adult
patients (>14 years) with suspected severe leptospirosis,
deﬁned as patients presenting with acute fever (oral tempera-
ture, ‡38.0C for <15 days) in the absence of an obvious focus
of infection, and who, in the opinion of the attending physician,
might have pulmonary involvement (i.e. history of haemoptysis
and/or bilateral nodular or air space inﬁltration). Patients who
were pregnant or breastfeeding, those with history of bleeding
disorder, those who had underlying diseases such as chronic
liver disease or diabetes mellitus, and those receiving diuretics
or glucocorticoids were excluded. The study protocol was
approved by the Ethical Review Subcommittee of the Public
Health Ministry of Thailand and written informed consent was
obtained from all of the study volunteers.
Sample size requirements
The study was designed to evaluate the efﬁcacy of desmo-
pressin and high-dose (pulse) dexamethasone as adjunct
treatment for pulmonary involvement associated with severe
leptospirosis compared to standard critical care (controls).
Twenty-three patients in each group were required to detect
a reduction in mortality from 60% in the control group to
20% in either desmopressin or pulse dexamethasone adjunct
treatments with 95% conﬁdence and 80% power.
Randomization and study protocol
Patients were randomly allocated to receive either 0.3 lg/kg
of desmopressin in 50 mL of saline, as a 30-min infusion
(desmopressin group); or 200 mg of intravenous infusion of
dexamethasone once daily for 3 days followed by 1 mg/kg/
day oral prednisolone for 4 days (pulse dexamethasone
group); or neither (control group). Desmopressin could be
repeated two or three times at 12- or 24-h intervals if
bleeding persisted. Dosage regimens of desmopressin and
dexamethasone used in the study were based on published
case series [10,13]. All patients received a combination of
ceftriaxone or cefotaxime and doxycycline during the ﬁrst
48 h of admission. Treatment was then continued or
switched to other antimicrobials according to results of the
initial blood cultures. Other supportive measures were pro-
vided based on the decision of the attending physician.
Baseline investigations included history, clinical examina-
tion, a full blood count, plasma glucose and electrolytes,
serum urea and creatinine, liver function tests, prothrombin
time and activated partial thromboplastin time, two aerobic
blood cultures, urine analysis and chest radiography. An addi-
tional 5 mL of blood was placed into a sterile EDTA bottle
for a PCR assay. Patients who were admitted with acute
respiratory distress or multi-organ dysfunction, and/or
required mechanical ventilation, were admitted to the inten-
sive care unit as soon as possible.
Patients were discharged when the oral temperature had
fallen to £37.5C for at least 48 h. Convalescent sera for
serological assays were collected 1–2 weeks after discharge.
Sera were stored at )20C until tested. Plasma from EDTA
blood was stored at )70C until tested. Data collection was
carried out by the study team, who were unaware of the
study hypothesis.
Conﬁrmation of leptospirosis
Leptospirosis was conﬁrmed by the World Health Organiza-
tion criteria [14]. Acute and follow up sera were tested by
the microscopic agglutination test (MAT), as previously
described [14]. Reference Leptospira from 24 serogroups
including serovars known to be prevalent in Thailand were
used as the antigen in the MAT. A PCR assay targeting spe-
ciﬁc outer membrane protein (lipL21) of Leptospira was per-
formed as previously described [15]. The diagnosis of
leptospirosis was made by either positive PCR or either a
four-fold or greater rise in antibody titre, or a titre of at
least 1 : 400 on a single specimen.
Criteria for the diagnosis of rickettsial infections (scrub
typhus and murine typhus) were either at least a four-fold
rise in speciﬁc anti-rickettsial IgG or IgM (using an immuno-
ﬂuorescent antibody test.) titre between paired serum sam-
ples to a titre of at least 1 : 200, or a single titer or stable
IFA titre of 1:400 or greater [16].
Patients with conﬁrmed leptospirosis were classiﬁed pro-
spectively by organ system involvement manifested by hypoten-
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sion (systolic blood pressure of <90 mmHg or a sustained
decrease in systolic blood pressure ‡40 mmHg); jaundice (a
rise in total bilirubin to ‡50 lmol/L (normal range 5–17 lmol/
L); renal dysfunction (either oliguria i.e. urine output <0.5 mL/
kg/h for at least 1 h, or azotemia (serum creatinine of
‡265 lmol/L); pulmonary involvement (abnormal chest radio-
graph or requirement for mechanical ventilation on admission);
decreased level of consciousness; or hemorrhagic complica-
tions such as haemoptysis, or gastrointestinal bleeding.
Analysis of results
The efﬁcacy of desmopressin or pulse dexamethasone was
analyzed on an intention-to-treat and a per-protocol basis.
Intention-to-treat analysis was based on all patients who
were enrolled into the study. Per-protocol analysis was per-
formed for patients with laboratory-conﬁrmed leptospirosis.
The primary outcome measure was mortality rate. The sec-
ondary efﬁcacy outcomes were the duration of mechanical
ventilation in days and the duration of bleeding measured in
hours from the time of enrollment to the last recorded
presence of blood in body secretions or excreta.
Adverse events were deﬁned as the development of new
symptoms or signs after the administration of a study drug.
Analyses of baseline characteristics and adverse events were
performed on an intention-to-treat basis.
Statistical analysis
All statistical analyses were performed using SPSS, version
13.5 (SPSS Inc, Chicago, IL, USA). Chi-square or Fisher’s
exact tests were used to compare rates and proportions and
Mann–Whitney U- and unpaired t-tests were used to analyze
continuous variables. All p values were two tailed; p £0.05
was considered as statistically signiﬁcant. Outcomes were
compared between each adjunct treatment group and logistic
regression analysis was used to determine independent risk
factors for death.
Results
The present study was performed between July 2003 and
October 2006. The trial was stopped early because of difﬁ-
culty in enrollment as a result of a reduction in the number
of patients with suspected severe pulmonary involvement
associated with leptospirosis over time. A total of 68
patients were studied (23 patients in the desmopressin
group, 22 in the pulse dexamethasone group and 23 in
the control group). The diagnosis of leptospirosis was
conﬁrmed in 52 patients (77%) by PCR in nine patients and
by MAT in 43 patients. Of the 16 patients who were not
diagnosed as having leptospirosis, six had rickettsial infec-
tions (scrub typhus in ﬁve and murine typhus in one) and
two had septicaemic melioidosis; the ﬁnal diagnosis was
unknown in eight patients.
Demographic data, baseline clinical characteristics and lab-
oratory investigations on admission were comparable
between the groups (Table 1). All patients received ceftriax-
one or cefotaxime plus doxycycline treatment during the
ﬁrst 48 h. Other supportive measures were similar in the
three study groups (Table 2).
TABLE 1. Demographic data, clini-
cal characteristics and baseline lab-
oratory tests on admission
Desmopressin
Pulse
dexamethasone Control
Total 23 22 23
Male, n (%) 19 (83) 20 (91) 21 (91)
Median age, years (range) 40 (16–73) 38 (18–64) 34 (16–60)
Median days of illness (range) 5 (1–8) 5 (2–14) 4.5 (1–7)
Vital signs, median (range)
Body temperature (C) 37 (36–40.3) 36.7 (35.7–40.3) 37 (35–39.5)
Respiration rate/min 24 (20–36) 28 (20–40) 24 (20–2)
Mean arterial pressure (mmHg) 70 (40–110) 76 (50–110) 75 (17–102)
Haemoptysis, n (%) 19 (83) 19 (86) 20 (87)
Jaundice, n (%) 17 (74) 15 (68) 15 (65)
Renal dysfunction, n (%) 20 (87) 16 (73) 19 (83)
Thrombocytopenia, n (%) 18 (78) 13 (59) 20 (87)
Abnormal chest X-ray, n (%) 21 (91) 22 (100) 20 (87)
Laboratory results, median (range)
Haematocrit (%) 31.2 (14.8–46) 31.3 (14.8–56) 31.6 (23.6–45.9)
White blood cell (· 103/L) 13.1 (3.6–37.1) 13.7 (4.4–42.3) 10.5 (1–34.8)
Platelets (· 109/L) 42.5 (10–280) 45 (9–538) 32.5 (10–158)
Total bilirubin (lmol/L) 69.7 (3.4–443.7) 120.7 (5.1–589.9) 93.5 (10.2–518.5)
Serum creatinine (lmol/L) 319.2 (79.8–886.7) 319.2 (53.2–1560) 416.7 (62.1–1135)
Maximum creatinine (lmol/L) 416.7 (97.5–1090.5) 390.1 (88.7–1622.5) 523.1 (115.3–1134.8)
Worst PaO2/FiO2 ratio* 152.5 (59–456.7) 143.3 (45–695.2) 122 (57–458.3)
Data are available in 14/23, 14/22 and 14/23 patients of the desmopressin, pulse dexamethasone, and control group,
respectively.
*p values were >0.05 in all variables compared among the three study groups.
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Fifteen patients died (22%), of whom eight were in the
desmopressin group, four were in the pulse dexamethasone
group and three were in the control group (p=0.19). Seven
of the deaths occurred within 48 h of admission. The diagno-
ses in patients who died were leptospirosis in eight, scrub
typhus in three and unknown in four. Abnormal chest radio-
graphs were found in 13 patients who died (cardiomegaly
and appearances consistent with congestive heart failure in
three, bilateral alveolar inﬁltration in nine and mixed reticu-
lar and alveolar inﬁltration in one). All but one patient who
died had acute renal failure, and ten of 15 (67%) had jaun-
dice. The cause of death was multi-organ failure in 13
patients. Nosocomial pneumonia was the cause of death in
two patients with conﬁrmed leptospirosis, both of whom
had received pulse dexamethasone. In laboratory-conﬁrmed
leptospirosis, two deaths occurred in the control group
compared to ﬁve in the desmopressin group and one in the
pulse dexamethasone group.
A Cox proportional hazard model was used to predict
the outcome of treatment adjusted for age, sex, duration of
illness, systolic blood pressure, respiration rate, serum creat-
inine, serum total bilirubin, serum potassium and platelet
count on admission. Serum creatinine was a signiﬁcant risk
factor associated with mortality in intention-to-treat patients,
whereas serum total bilirubin was signiﬁcantly associated
with mortality in patients with laboratory-conﬁrmed leptospi-
rosis (Table 3). Adjunct treatment with either pulse dexa-
methasone or desmopressin did not affect the outcome.
Discussion
Severe manifestations of leptospirosis are hepatorenal dys-
function, sepsis syndrome, and bleeding (such as haemoptysis
or hematemesis) [2–6]. Diffuse alveolar haemorrhage pre-
senting as haemoptysis and dyspnea is the most serious pul-
monary complication. The reported incidence of severe
pulmonary haemorrhage associated with leptospirosis has
varied from 3.7% (with 70% mortality) in Peru [17] to 19%
(with 42% mortality) in the Seychelles [4]. The cause of
TABLE 2. Treatment and outcome
of the three study groups (inten-
tion-to-treat)
Outcome Desmopressin
Pulse
dexamethasone Control p value
Mechanical ventilation, n (%) 13 (57) 17 (77) 16 (69.6) 0.28
Other adjunctive treatment, n (%)
Platelet transfusion 10 (43) 10 (46) 14 (60.9) 0.42
Vitamin K injection 9 (39) 13 (59) 11 (48) 0.38
Dopamine infusion 16 (69.6) 13 (59) 16 (70) 0.69
Hemodialysis 5 (21.7) 6 (6) 7 (30) 0.79
Survived, n (%) 15 (65.2) 18 (82) 20 (87) 0.18
Died within 24 h 5 1 2
In conﬁrmed leptospirosis cases 12/17 (71) 14/15 (93) 18 (90) 0.14
Median duration (range) of
Mechanical ventilation (days) 5 (1–17) 6 (1–25) 7 (1–17) 0.35
Bleeding after enrollment (h) 72 (24–168) 72 (8–138) 96 (12–240) 0.18
Admission (days) 7 (1–19) 10.5 (2–34) 9 (1–30) 0.05
Adverse event
No 21 (91) 14 (64) 22 (96) 0.04
Yes
Nosocomial infection 0 6 1
Hyperglyceamia 0 1 0
Hyponatraemia 1 0 0
Rash 1 0 0
Intracranial haemorrhage 0 1 0
TABLE 3. Results of logistic regres-
sion analysis to determine the inde-
pendent risk factor for mortality in
all study patients, and in patients
with conﬁrmed leptospirosis
Factor
All patients Conﬁrmed leptospirosis
OR* (95% CI) p value OR* (95% CI) p value
Age 1.035 (0.987–1.085) 0.155 0.998 (0.916–1.087) 0.962
Duration of fever 1.066 (0.775–1.467) 0.693 0.914 (0.488–1.711) 0.779
Systolic blood pressure 1.013 (0.986–1.041) 0.346 1.013 (0.965–1.063) 0.610
Respiration rate 1.051 (0.947–1.167) 0.348 1.083 (0.965–1.063) 0.353
Adjunct treatment
Pulse dexamethasone 0.354 (0.05–2.501) 0.298 0.036 (0.001–2.45) 0.123
Desmopressin 2.438 (0.495–12.00) 0.273 1.582 (0.086–29.23) 0.758
Serum potassium 0.82 (0.371–1.813) 0.624 1.887 (0.66–5.397) 0.236
Serum creatinine 1.28 (1.036–1.581) 0.022 1.277 (0.834–1.954) 0.260
Total bilirubin 0.92 (0.841–1.007) 0.071 0.759 (0.598–0.965) 0.024
*Adjusted.
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death was either massive pulmonary haemorrhage or acute
respiratory distress syndrome or multi-organ failure. The
present study showed that Orientia tsutsugamushi (the causa-
tive organism of scrub typhus) and Burkholderia pseudomallei
(the causative organism of melioidosis) can also cause haem-
optysis, pneumonitis, and multi-organ failure, mimicking
severe leptospirosis.
The incidence and the mortality of severe pulmonary
haemorrhage associated with leptospirosis have decreased
over time in Thailand. An increased awareness amongst phy-
sicians in Thailand of severe leptospirosis has led to earlier
antimicrobial treatment and aggressive intensive care therapy.
This may explain the markedly lower overall mortality of
severe leptospirosis in the present study compared to previ-
ous ones [4,17].
The inﬂammatory response in leptospirosis is relatively
mild compared to the amount of vascular damage in severe
cases. The presence of antibodies (IgG and IgA) and comple-
ment (C3), together with the paucity of leptospires in lung
tissue found in both experimental animals [8] and autopsy
material from patients who died with acute respiratory fail-
ure [9], suggests that infecting Leptospira might have precipi-
tated an autoimmune process, leading to pulmonary
haemorrhage through damage to the alveolar septa. High-
dose steroid was found to be an effective adjunct to the
treatment of severe pulmonary haemorrhage in patients with
leptospirosis in two case series reported from India [9,10].
We could not conﬁrm the efﬁcacy of this adjunct treatment
in this control study. Although the mortality in the high-dose
dexamethasone group was not signiﬁcantly different from the
controls, dexamethasone treatment was associated with nos-
ocomial pneumonia in two patients.
The whole-genome sequencing of Leptospira interrogans
serovars lai has suggested alternative pathogenic mechanisms.
Genes encoding several proteins with homology to animal
proteins important in haemostasis were identiﬁed, including
platelet-activating factor acetylhydrolase and von Willebrand
factor type A domains [18]. This organism may therefore
directly activate the haemostasis pathway. Desmopressin
triggers the release of endothelial haemostatic factors, short-
ens prolonged bleeding times, enhances platelet adhesiveness
to injured vessels, and induces von Willebrand factor secre-
tion by activating endothelial cell V2 receptors. These recep-
tors have been identiﬁed recently in human lung tissues and
cultured human lung microvascular endothelial cells [19].
Desmopressin has also proved to be effective in the bleeding
associated with hepatic and renal failure [12], and this also
supports its use in patients with leptospirosis. However,
although other studies have reported desmopressin to be an
effective adjunct to the treatment of massive pulmonary
haemorrhage in patients with leptospirosis [13], we did not
conﬁrm this in the present randomized controlled trial.
The present study was conducted in a subgroup of
patients who had severe leptospirosis, most of whom had
multi-organ dysfunction on admission. Despite desmopressin
or pulse dexamethasone adjunct therapy, eight patients with
laboratory-conﬁrmed leptospirosis died, most of them within
48 h of admission from irreversible multi-organ failure.
Although they presented with haemoptysis and bilateral pul-
monary inﬁltrates consistent with diffused alveolar haemor-
rhage, massive lung haemorrhage was not found to be a
main cause of death in these patients. This suggests that the
pathogenesis of multi-organ failure and septic shock in lepto-
spirosis is similar to septic shock caused by other bacteria
and that this was not affected by desmopressin or pulse
dexamethasone.
The observed mortality in the present study was much
less than expected and the number of patients with con-
ﬁrmed leptospirosis did not reach the target number. There-
fore, the present study has limited statistical power to
detect treatment differences in patient with conﬁrmed lepto-
spirosis. However, the results obtained in the present study
do not support the use of either high-dose dexamethasone
or desmopressin as the adjunctive treatment of pulmonary
involvement associated with severe leptospirosis. Early diag-
nosis and aggressive critical care supportive therapy are key
factors in the reduction of mortality in these patients.
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